Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma

Gynecologic Oncology

Volumn 102, Issue 3, 2006, Pages 421-424

  Tewari, Devansu ^a   Saffari, Bahman ^a   Cowan, Carol ^a   Wallick, Anita C ^a   Koontz, M Zach ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ET 743; Metastatic uterine leiomyosarcoma; Trabectiden; Yondelis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MESNA; TRABECTEDIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS CANCER; UTERUS LEIOMYOSARCOMA; UTERUS SARCOMA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DRUG ADMINISTRATION SCHEDULE; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; LEIOMYOSARCOMA; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; TETRAHYDROISOQUINOLINES; UTERINE NEOPLASMS;

EID: 33748450682     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.04.025     Document Type: Article

References (10)

1. Major F.W., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early stage uterine sarcoma. Cancer 71 Suppl. 4 (1993) 1702-1709
2. Look K.Y., Sandler A., Blessing J.A., Lucci J.A., and Rose P.G. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol 92 2 (2004) 644-647
3. Van Kesteren C.H., de Vooght M.M., Lopez-Lazarao L., Mathot R.A., Schellens J.H., Jimeno J.M., et al. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. Anticancer Drugs 14 7 (2003) 487-502
4. Yovine A., Riofrio M., Blay J.Y., et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22 5 (2004) 890-899
5. Garcia-Carbonero R., Supko J.G., Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 8 (2004) 1480-1490
6. Le Cesne A., Blay J.Y., Judson I., et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23 3 (2005) 576-584 [Erratum in: J Clin Oncol 2005;23(22):5276]
7. Garcia-Carbonero R., Supko J.G., Maki R.G., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23 24 (2005) 5484-5492
8. Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T., et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 4 (1983) 626-632
9. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20 12 (2002) 2824-2831
10. Twelves C., Hoekman K., Bowman A., et al. Phase I and pharmacokinetic study of Yondelis (ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 39 13 (2003) 1842-1851